Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PSA Screening Overdiagnosis Rises Sharply With Age

2.

Integrative palliative care is critical to improving mental health among pancreatic cancer patients

3.

Outcomes in Resected Melanoma Influenced by Timing of Recurrence

4.

Remote CBT for Insomnia Improves Symptoms During Chemo

5.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot